User Fee Goal Dates
Executive Summary
Estimated FDA review deadlines for pending applications. Updated weekly.
You may also be interested in...
Shutdown Week Four: FDA Maintains Pre-Shutdown Output Pace In Some Cases
ANDA and NDA/BLA supplement approvals continue thanks to carryover user fee funds, but US FDA hasn't made any NDA and BLA approvals during shutdown as as anxiety over effect of "lapse period" on agency increases.
Sage's Postpartum Depression Drug Brexanolone Faces Loss-Of-Consciousness Questions
US FDA is recommending a REMS requiring continuous monitoring during the 60-hour infusion and no home use, a potential problem for commercial marketing.
US FDA Eliminating 'Sub-Indications' From Inflammatory Bowel Disease Labels
Claims such as induction of clinical remission will now be placed in the clinical studies section for new IBD approvals.